Abstract 762
Background
Advanced age is an important risk factor of cancer and is associated with poor prognosis. Changes in the immune system called immunosenescence may occur with older age. However, the impact of aging on efficacy and safety of immune checkpoint inhibitors (ICI), such as anti-PD(L)1, remains undetermined.
Methods
Patients with advanced solid tumours treated with an anti-PD(L)1 agent monotherapy between June 2014 and October 2017 and prospectively included within the Gustave Roussy ICI-dedicated pharmacovigilance registry REISAMIC (Registre des Effets Indésirables Sévères des Anticorps Monoclonaux Immunomodulateurs en Cancérologie) were retrospectively reviewed. Incidence of immune-related adverse events (irAEs) of grade ≥2 was compared between patients aged ≥ 70 and < 70 years old using Chi-squared test.
Results
Among the 615 patients included in the analysis, 191 were ≥ 70 years old (OP) and 424 < 70 years old (YP). The median age of OP and YP were respectively 77 (70 - 93) and 59 (17 - 69). A total of 165 irAEs were included in the analysis (103 Grade 2 and 58 Grade 3-4). The overall occurrence of irAEs grade ≥ 2 was higher in OP compared to YP (33% versus 25%, p = 0.03). Statistical significance was lost when stratifying irAEs according to their severity grade, suggesting that this effect was constant whatever the grade (p = 0.08 for Grade 2 and p = 0.13 for Grade 3-4). Anti-PD(L)1-related deaths were registered in 1 OP and 3 YP (0.5% and 0.7% respectively; NS). The most frequent organs toxicities in OP were skin rash (49%), endocrine (14%), hepatic (10%); it was skin rash (28%), endocrine (25%), digestive (15%) in YP. Median time to toxicity was similar between the two groups (7 weeks in YP and 6 weeks in OP, p = 0.31).
Conclusions
Anti-PD(L)1 immunotherapies are an acceptable treatment option for OPs, by being aware that immune related adverse events are more frequent in this population. Further dedicated studies are warranted to explore prospectively immune-related safety in OPs. Impact: Older patients should be monitored closely as they may be at risk of increased significant immune-related toxicity compared to their younger counterparts.
Clinical trial identification
Legal entity responsible for the study
C. Baldini.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
S. Champiat: Consulting: AstraZeneca, BMS, MSD, Roche, Janssen, Novartis. J-C. Soria: Employee: AstraZeneca Medimmune; Honoraria, Advisory role: Astex, Clovis, GSK, Gammamabs, Lilly, MSD, Merus, Pfizer, Pharmamar, Pierre Fabre, Roche Genentech, Sanofi, Servier, Takeda. C. Massard: Honoraria, Consultancy fees: Sanofi, Janssen, Astellas, Genetech, Orion, Medimmune, Ipsen. A. Marabelle: Honoraria, Consultancy fees: AstraZeneca, BMS, Merck, Sanofi, Janssen, Astellas, Genetech, Orion, Medimmune, Ipsen. All other authors have declared no conflicts of interest.
Resources from the same session
2300 - AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)
Presenter: Claudia Cardone
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2834 - Multimodal detection of homologous recombination repair gene mutations (HRRm) in a Phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Thomas Carr
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3596 - Identification of a highly suppressive Treg subset associated to immunotherapy response
Presenter: Emilio Giunta
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3705 - A Novel Framework for Evaluating Biomarker Response Relationships in Immuno-oncology (IO)
Presenter: Jeffrey Evelhoch
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5332 - Comparison of OncoBEAM and NGS methods to detect plasma EGFR T790M mutations at progression of NSCLC
Presenter: Jessica Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5700 - Differential expression of PD-L1 and immune biomarkers by age: Decreased expression in pediatric/AYA patients with advanced cancer
Presenter: Omid Hamid
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
966 - Potential resistance mechanisms revealed primary resistance to crizotinib in ROS1+ non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Quxia Zhang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2171 - Prevalence of CLDN18.2, HER2, and PD-L1 in Gastric Cancer Samples
Presenter: Diarmuid Moran
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
2318 - Epigenetic markers in circulating cell-free DNA for detection of early stage colorectal cancer
Presenter: Yanqun Liu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
3625 - Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292
Presenter: Benjamin Besse
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract